Positive top-line results from NPSP558 Phase 3 study on hypoparathyroidism
Links shared publicly online about this topic.
- 0total visits
Positive top-line results from NPSP558 Phase 3 study on hypoparathyroidism
NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today announced positive top-line results from REPLACE, a Phase 3 registration study of NPSP558, the company's bioengineered replica of human parathyroid hormone (rhPTH 1-84), in adult hypoparathyroidism patients.
View full resource at news-medical.net
Tags: Endocrinology, Parathyroid Disorder, Osteoporosis, Pharma, Phase 3 Clinical Trial, News, Hypoparathyroidism
Most Recently Shared on November 7, 2011 at 11:23 pm By:
Osteoporosis News: Positive top-line results from NPSP558 Phase 3 study on hypoparathyroidism: NPS Pharmaceutica... http://t.co/IZ3Ahqd1
Phase 3 Study of NPSP558 for Hypoparathyroidism in Adults - MPR
empr.com — “NPS Pharmaceuticals announced positive results from its Phase 3 REPLACE study of NPSP558 for the treatment of hypoparathyroidism in adults.” View full resource at empr.com
Most Recently Shared on November 7, 2011 at 5:54 pm By:
Phase 3 Study of NPSP558 for Hypoparathyroidism in Adults http://t.co/IZAgYjGd #thyroid
Advertisement
